Myeloproliferative Neoplasms Forecast in 12 Major Markets 2017-2027

News provided by

03 Nov, 2017, 18:45 GMT

DUBLIN, November 3, 2017 /PRNewswire/ --

The "Myeloproliferative Neoplasms Forecast in 12 Major Markets 2017-2027" report has been added to Research and Markets' offering.

Myeloproliferative neoplasms (MPNs) are a group of diseases that concern the clonal proliferation of precursors of the myeloid lineage cells in the bone marrow. MPNs are characterized by uncontrolled cell growth, and therefore can also be classified as a type of blood cancer.

This report provides the current prevalent population for three types of MPNs: polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF), across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Japan, China, India, Brazil) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight, JAK2-V617F mutation status, several clinical and laboratory parameters, as well as some main symptoms and co-morbidities of the covered MPNs and features thereof have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for MPNs include:

Thrombosis
Splenomegaly
Hepatomegaly
Incident leukaemia
Anaemia
Portal hypertension

Key Topics Covered:

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Comorbid Conditions / Features Associated With the Disease
Methodology for Quantification of Patient Numbers
Top-Line Prevalence for Myeloproliferative Neoplasms
Top Line Prevalence for Polycythaemia Vera
Top Line Prevalence for Essential Thrombocythaemia
Top Line Prevalence for Primary Myelofibrosis
Features of Myeloproliferative Neoplasms Patients
Features of Polycythaemia Vera Patients
Features of Essential Thrombocythaemia Patients
Features of Primary Myelofibrosis Patients
Comorbid Conditions of Myeloproliferative Neoplasms Patients
Comorbid Conditions of Polycythaemia Vera Patients
Comorbid Conditions of Essential Thrombocythaemia Patients
Comorbid Conditions of Primary Myelofibrosis Patients
Abbreviations Used in the Report
Other Publications
Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data & Platforms
References
Appendix

For more information about this report visit https://www.researchandmarkets.com/research/zbkl28/myeloproliferative

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

Myeloproliferative Neoplasms Forecast in 12 Major Markets 2017-2027